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Our objective was to design a genotyping platform that would allow rapid genetic characterization of
samples in the context of genetic mutations and risk factors associated with common neurodegenerative
diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and
accessible technology. Central to this project, we wanted to make the content of the platform open to any
investigator without restriction. In designing this array we prioritized a number of types of genetic
variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and
other functionally important variants. The array was primarily designed to allow rapid screening of
samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit
aim was to make this array widely available to facilitate data sharing across and within diseases. The
resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping.
NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants,
and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at
approximately $50e$60 per sample using a 12-sample format chip and regular Infinium infrastructure;
thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX,
discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control
metrics and a brief primer for the analysis of NeuroX derived data.
Published by Elsevier Inc.1. Introduction
The availability of economical custom content additions to
genome-wide or exome-wide genotyping arrays has permitted the
development of tail;ored arrays for both genetic discovery and
replication efforts. In the last few years, it has become evident that in
the second wave of genome wide association (GWA) investigatorsding, please see the consortia
cs, National Institute on Aging,
79; fax: þ301 451 5466.
on).
Inc.sought to investigate variants below the threshold of genome-wide
significance and fine map extant signals. Such an effort requires
large-scale replication efforts involving the assay of large numbers of
samples, and the interrogation of a very large number of candidate
variants. A fairly inefficient approach to this problemwas being used,
where investigators representing single disease research groups
pursued replication in isolation of other efforts both within and
across diseases. In 2011, the National Institute of Neurological Disor-
ders and Stroke convened a meeting that included investigators
researching myriad common neurodegenerative diseases with the
intent of identifying a more efficient solution. This meeting involved
representatives from genetics groups leading GWA in Alzheimer’s
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis
(ALS), multiple sclerosis, and frontotemporal dementia (FTD), among
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array that could type variants of interest for all major neurodegen-
erative diseases would be of great utility; such an array had the po-
tential to benefit from an economy of scale, to reduce cost by allowing
easy sharing of controls and allow direct comparison of genetic data
across diseases. In response to that consensus, we modified the
design of an array originally intended to serve as a replication assay
for a large PD meta-analysis to include a wide variety of content
relevant to the broader neurodegenerative disease research com-
munity. Here, we describe the content and use of this array, called
NeuroX.
In this effort, summary statistics for the largest available
genome-wide association studies (GWAS) were mined to nomi-
nate known and candidate loci tagging risk for AD, FTD, multiple
system atrophy (MSA), myasthenia gravis, Charcot Marie Tooth,
progressive supranuclear palsy (PSP), ALS, and PD. Where avail-
able, putative risk variants identified by exome sequencing of fa-
milial and population based samples, as well as those derived from
literature review for the previously mentioned diseases, were also
included on the array. We also performed a systematic literature
and database search for all mutations known to cause neurologic
disease. Technical redundancies and reliable proxies were used for
priority SNPs to guarantee quality genotyping calls produced by
the array. This custom Neuro content includes over 24,000
neurodegenerative-focused variants; this custom library can be
added to many off-the-shelf Illumina Infinium products; however;
here we describe the use of this library when added to Illumina’s
Infinium HumanExome BeadChip, a product we have named
NeuroX. Thus NeuroX includes full exome sequencing based
variability standard to the Illumina HumanExome array v1.1
(242,901 variants) and neurologic and neurodegenerative disease
focused content (24,706 variants). In addition to the ability to add
the custom Neuro library to other illumina genotyping arrays, it is
also relatively easy to add new custom variants should the need
arise. In this article however, we describe the initial version of the
NeuroX array comprising the base exome and existing custom
content.
From its inception, the NeuroX array was designed to be a rapid
and cost effective solution for high quality genotype data. The
current cost of the array is approximately $57 per sample and
genotyping of thousands of samples per week is achievable in most
core laboratories, with this estimate including reagents but
excluding labor and previous Illumina infrastructure costs. It is also
notable that we are in the process of making a large amount of
NeuroX data publicly available (dbgap address pending).
2. Methods
2.1. Array design
The custom content available on the NeuroX array was taken
from 3 primary sources: large-scale GWAS, high throughput
sequencing of families and cohort studies, and literature searches to
identify risk factors and disease-causing mutations.
For GWAS based data sets we mined participant level data,
when available, for diseases such as PD, ALS, FTD, and myasthenia
gravis, including both published and unpublished data sets
(ALSGEN Consortium et al., 2013; Chiò et al., 2009; Do et al., 2011;
International Parkinson Disease Genomics Consortium et al.,
2011; International Parkinson’s Disease Genomics Consortium
(IPDGC) and Wellcome Trust Case Control Consortium 2
(WTCCC2), 2011; Lill et al., 2012; Mok et al., 2012). Participant
level GWAS data for AD and PSP were not available to our group
at the time of chip design, so publicly available GWA loci for these
diseases were included (1000 Genomes Project Consortium et al.,2012; Höglinger et al., 2011; Hollingworth et al., 2011; Lambert
et al., 2009). Genome-wide significant loci from diseases of in-
terest were included with either multiple proxies for the top SNP
at every locus, or technical replicates, if proxies were not avail-
able. We have included up to 5 variants per significant locus. Loci
were defined as any SNP reaching a genome-wide significant p-
value and correlated at r2 < 0.50 with any other significant SNPs
within 250 kilobases for each disease of interest. All analyses
were derived from at least 1000 Genomes level SNP coverage and
used participant level data from the 1000 Genomes project to
nominate proxies when possible. In addition, locus tagging SNPs
were included to allow for the identification of new loci in larger
sample series. For all SNPs associated in GWAS with diseases of
interest that reached candidate p-values of 1  104 or stronger,
additional haplotype-tagging SNPs were placed on the NeuroX
array, in an attempt to facilitate future genotype imputation ef-
forts. Tagging SNPs were selected based on an r2 in 1000 Ge-
nomes samples at less than 0.50 with any other SNPs meeting the
same p-value threshold within a 250 kilobase window, allowing
for regional assessments of genetic variability. Whenever
possible, GWAS based SNPs that were not the most significant
within the locus were replaced by a proxy meeting the previously
mentioned criteria if array design scores for the probe associated
with that SNP failed (quality less than 0.80 and no array valida-
tion), as a means of only using higher quality SNPs on the NeuroX
array. This led to the successful inclusion of almost 16,000 GWAS-
derived variants or GWAS-related variants across multiple dis-
ease sources.
Sequence-based data generated by pilot studies within our
consortia (both exome and genome sequencing) were mined to
nominate rare and coding variants for inclusion on the NeuroX
array. These data come from familial and cohort studies looking into
AD, MSA, FTD, Charcot Marie Tooth, MSA, PSP, ALS, and PD. Cohort-
derived sequence-based data were inclusive of any rare and coding
variants at a frequency of less than 5% in the population fromwhich
the pilot data were collected. For data extracted from family-based
sequencing studies, variants were filtered and only those not
appearing in the 1000 Genomes Project and the NHLBI Exome
Sequencing Project database were included (1000 Genomes Project
Consortium et al., 2012; NHLBI GO Exome Sequencing Project,
2011). This led to the successful inclusion of 7485 rare sequence-
based variants.
An extensive systematic review of published literature was
performed to include variants known to be involved in neurologic
or neurodegenerative diseases for nomination onto the array.
Briefly, we performed PubMed searches using the gene name and
the word “mutation” as search parameters to identify articles
describing mutations. The genes searched for were: ABCA7, ACE,
APOE, APP, ATP13A2, BACE1, CHMP2B, CLCN6, CLN3, CLN5, CLN6,
CLN8, CSF1R, CST3, CTSD, DNAJC5, ECE2, FBXO7, FUS, GBA, GLA, GLB1,
GRN, GUSB, HEXA, HEXB, LRRK2, MAPT, MFSD8, NEU1, NOTCH3,
NPC1, NPC2, PANK2, PARK2, PARK7, PINK1, PLA2G6, PPT1, PSAP,
PSEN1, PSEN2, SGSH, SNCA, SORL1, SPTLC1, TARDBP, TPP1, TREM2,
TYROBP, VCP, and VPS35. We complemented this search by
including all the variants in the Parkinson Disease Mutation
Database and the Alzheimer Disease & Frontotemporal Dementia
Mutation Database (Cruts et al., 2012). In addition, updated GWAS
loci for any traits meeting p< 1108 in NHGRI GWAS catalog that
were not already on the basic exome content were added to the
array if the probe design score for that SNP was >0.8 (Hindorff
et al., 2009a, 2009b). Also, as part of this phase of array design,
special attention was paid to the APOE region with 34 variants
being dedicated to genotyping of the canonical epsilon-4 com-
pound genotype. This led to the successful inclusion of 1322 var-
iants. For ALS, we also mined variants from a number of databases
Fig. 1. For both NeuroX custom content and the standard content included on the array, most of the SNPs across the minor allele frequency spectrum have GenTrain scores >0.7,
suggesting quality genotype clusters are readily available. Discrepancies across content type are partially because of genotype cluster method differences between the 2 sets of
variants (custom and standard content) but also because of the inclusion of rare and difficult to genotype loci in the custom content of the array. Abbreviation: SNPs, single-
nucleotide polymorphisms.
Table 1
Comparison of content across standard and custom content
Content type Custom content Standard content
Numebr of variants 24,706 242,901
Variants less than MAF 0.01 (%) 31.531 82.277
Variants less than MAF 0.05 (%) 40.047 86.078
Variants at MAF 0.05 to 0.50 (%) 59.953 13.922
Mean MAF 0.148 0.031
Exonic variants (%) 36.151 96.504
Nonsynonymous
coding variants (% of exonic)
33.934 91.332
Data are based on clustering of over 14,000 Parkinson’s disease cases and controls as
described in (Nalls et al., 2014). All annotations from ANNOVAR (Wang et al., 2010).
Key: MAF, minor allele frequency.
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from HGMD and ALSOD all mutations in common (C9orf72
excluding repeat expansions, FUS, MATR3, OPTN, SOD1, SPG11,
TARDBP, UBQLN2, and VCP) and rare ALS genes (ALS2, ANG,
CHMP2B, DCTN1, FIG4, SETX, TAF15, and VAPB). To identify associ-
ation signals in and around known ALS genes, we mined 1000
Genome data to identify all multiethnic variants with minor allele
frequency (MAF) >0.01 located in common ALS gene bodies 100
kb. We then used Plink to identify haplotype-tagging SNPs (r2 >
0.50). For the ALS/FTD linked gene C9orf72, we mined variants
located within the 242 kb Finnish 42-SNP haplotype and 20 kb
(Laaksovirta et al., 2010, p. 21). To fine map exonic variation in
known ALS genes, we mined 1000 Genome data to identify all
multiethnic exonic variants with MAF >0 in common ALS genes.
2.2. Array genotyping
For the pilot analysis used to generate the data presented here,
approximately 14,000 samples were genotyped and multiple
calling methods tested. Samples tested were derived from a
number of sources including DNA from whole blood, EBV trans-
formed lymphocytes, and brain tissue. Genotyping was executed as
per the manufacturer’s protocol (Illumina, Inc). Our genotype
calling workflow used a publicly available cluster file for the exome
array standard content, which we modified to maximize variant
calling for the NeuroX custom content. This was accomplished
using a combination of the Illumina GenomeStudio automated
clustering algorithm, with manual inspection and modification for
the subset of the clusters not included in Grove et al. (2013). As part
of the array design process, we excluded a number of variants
based on low design quality scores, which allowed us to retain
diverse content and maximize the number of successfully typed
variants.
In addition, we imputed a random subset of 1000 European
ancestry unrelated individuals from a larger Parkinson’s disease
GWAS study that passed quality control after being genotyped on
the NeuroX array (Nalls et al., 2014) using the default settings of
MiniMac (Howie et al., 2012). Nonpalindromic SNPs passing
quality control and overlapping with those included in the
reference haplotypes (1000 Genomes Phase 1 Alpha Freeze
version 3, multiethnic panel) were used for imputation (1000
Genomes Project Consortium et al., 2012). This allowed us to
densely impute higher variant coverage into regions of interest
related to neurologic diseases GWAS based on the currently
available content on the array. In addition, we show that the
NeuroX array can be used for basic quality control similar to
standard GWAS, such as gender checking (evaluating concordancebetween self-reported and genetically determined genders as part
of quality control) or estimating continental ancestry based on
applying principal components analyses to common tagging SNPs
(Supplementary Figs. 1 and 2).3. Results and conclusions
Both NeuroX custom content and the standard HumanExome
based content show that most of the SNPs across the MAF spectrum
have GenTrain scores >0.7, suggesting high quality genotype clus-
ters are readily available (Fig. 1). As expected, lower MAFs are
associated with slightly lower genotype cluster qualities (p < 0.001
from linear regression models across MAF strata in Fig. 1 comparing
trends in GenTrain as MAF changes). GenTrain scores tend to be
only marginally lower for the custom content, which is not entirely
surprising, given that genotypes for these variants were clustered
and called on a reference of approximately 14,000 samples as
opposed to approximately 60,000 samples used to generate the
reference cluster file used to call genotypes for the standard exome
content.
Custom content on the NeuroX array spans 2236 megabases of
the autosome, only slightly less than the approximately 2600
covered by early GWAS arrays on which many previous studies of
neurodegenerative disease were based (Nalls et al., 2009). Mean
per megabase coverage of the custom content is 10.754 variants
per megabase, with a maximum of over 600 variants of interest
for fine mapping of particular regions, with a comparative bias
toward nonexonic and GWAS-derived variants (Table 1, Fig. 2).
The maximum coverage for the NeuroX custom content occurring
in regions of interest up to over 5-fold the depth of the standard
content in the same region. In comparison, the standard content
covers 2703 autosomal megabases at an average of 87.842
Fig. 2. Autosomal variant coverage per megabase for different content classes. Panel A, custom content coverage; panel B, standard content coverage; and panel C, coverage for
successfully imputed variants (imputation quality >0.30).
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regions surpassing 1000 variants per megabase. The inclusion of
tag SNPs within the GWAS-derived custom content in conjunction
with standard content variants have facilitated the successful
imputation of over 1.2 million SNPs (imputation quality >0.30).
Imputed variants from the NeuroX array cover 2703 megabases
and average 478.400 variants per megabase with a maximum
coverage up to over 16,500 variants per megabase in some re-
gions of interest.
As a proof of concept, we accurately tag known rare variants in
neurodegenerative disease. For example, the p.G2019S mutation in
LRRK2 (rs34637584) was confirmed to be completely concordant
for over 1000 samples genotyped using the NeuroX array that were
also assayed via taqman genotyping (Paisán-Ruíz et al., 2004). APOE
genotypes were extracted for a subset of over 2500 NeuroX assayed
samples overlapping with a previous study based on targeted
genotyping (Federoff et al., 2012) with only 93% accuracy to tag the
APOE epsilon-4 haplotype associated with Alzheimer’s risk. This
haplotype is made of 2 SNPs rs7412 and rs429358. The discordance
of APOE haplotypes between NeuroX and TaqMan genotyping was
entirely driven by discordance at rs429358, with complete
concordance at rs7412. Notably, we have identified rs429358 as a
low quality variant on NeuroX. Rs7412 is of acceptable quality, with
greater than 99% genotype concordance across 5 technical repli-
cates, a success rate mirrored at most of the redundant sites across
the array.
The data presented in this article unequivocally show that the
NeuroX array is a powerful and reliable tool for the investigation of
genetic factors associated with neurodegenerative disorders.
Although not designedwith clinical diagnosis in mind, we believe it
will serve as a powerful analytic tool for research purposes and
investigation of disease mechanisms. We have shown not only that
the content of the array is useful in assaying both rare risk variants
and common variability for use in future studies but also highly
valuable in investigating known risk loci in more detail. We fully
expect this array to become a starting point to the genetic analysis
of neurodegenerative disorders, given its relevant and up-to-date
genotyping content as well as its low cost. This custom array is
being treated as an on-going venture and is currently being adapted
to newer genotyping platforms outside of the standard exome array
content described here and tuned for better accuracy and higher
quality content, whereas still maintaining compatibility with cur-
rent offerings. Additionally, the fact that virtually all samples
derived from subjects with these disorders may be screened on the
same platform will provide researchers with tremendous power toperform not only analysis of a single phenotype but also to compare
different disease entities for overlaps or significant differences.
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